## WST: West Pharmaceutical Services, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.6% below STRENGTH zone (4.0-10.0%); PEG 3.38 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($257.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. West Pharma Heads to JPMorgan Healthcare Stage as Investors Watch Closely**
- Source: MyChesCo | 20251219T210820 | Somewhat-Bullish | Relevance: 100%
- West Pharmaceutical Services, Inc. (NYSE: WST) will present at the J.P. Morgan Healthcare Conference on January 14, 2026, an event closely watched by investors. The company, a major supplier of injectable drug containment and delivery systems, generated $2.89 billion in net sales for fiscal year 2024 and is a constituent of the S&P 500 index. Investors will be looking for insights into demand trends, manufacturing capacity, regulatory dynamics, and capital allocation plans.

**2. West Pharma Declares Dividend as Exton Giant Signals Steady Footing**
- Source: MyChesCo | 20251218T180842 | Bullish | Relevance: 100%
- West Pharmaceutical Services, Inc. (NYSE: WST) has declared a regular quarterly dividend of $0.22 per share, signaling stability to investors. The dividend is payable on February 4, 2026, to shareholders of record by January 28, 2026. This move highlights West Pharma's steady footing as a key supplier in the pharmaceutical industry, manufacturing injectable packaging and delivery components globally.

**3. Thrivent Financial for Lutherans Reduces Holdings in West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251219T103406 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly reduced its stake in West Pharmaceutical Services (NYSE:WST) by 33.4% in the second quarter, selling 14,656 shares and valuing its remaining holdings at approximately $6.39 million. Despite this, other major investors, including Durable Capital, Generation Investment Management, and Norges Bank, either initiated or substantially increased their positions, leading to institutional ownership of about 93.9%. The company reported strong Q2 earnings, beating analyst estimates, and provided positive FY2025 guidance, alongside a consistent quarterly dividend.

**4. Corient Private Wealth LLC Sells 6,498 Shares of West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251219T090721 | Neutral | Relevance: 100%
- Corient Private Wealth LLC reduced its stake in West Pharmaceutical Services, Inc. by 11.3%, selling 6,498 shares and now owning 50,933 shares valued at $11.14 million. The article also details other institutional investor activity, analyst ratings, financial performance, and dividend information for West Pharmaceutical Services.

**5. West Pharmaceutical Services (WST): Reassessing Valuation After a 20% Share Price Decline**
- Source: Yahoo Finance Singapore | 20251217T051356 | Somewhat-Bullish | Relevance: 100%
- West Pharmaceutical Services (WST) has seen a 20% share price decline over the past year despite growing revenue and net income, prompting a reassessment of its valuation. While a narrative model suggests the stock is undervalued with a fair value of $346.07, its current P/E ratio of 39x is above the industry average, implying potential overvaluation. This creates a debate on whether the market is already pricing in future growth or if the stock presents an undervalued opportunity.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.38 signals overvaluation risk, limited margin of safety. Forward P/E 35.0x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.6B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.38 |
| Forward P/E | 35.0 |
| Current P/E | 38.4 |
| YoY Growth | 9.6% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 0.5% to -0.6% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.6pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). RSI neutral at 51. Elevated volume (1.7x 20MA), institutional activity likely. OFD pattern: +SLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.61% (CS: 44) | Neutral |
| RSI_14 | 50.8 | Neutral |
| MACD Histogram | -0.31 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 1.129x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $272.44
- **Stop Loss:** $257.10 (5.6% risk)
- **Target:** $287.78 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 78
- **Position Value:** $21,250.32
- **Portfolio %:** 21.25%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*